NanoViricides, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNVC research report →
Price Chart
About the company
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses.
- CEO
- Anil R. Diwan
- IPO
- 2005
- Employees
- 7
- HQ
- Shelton, CT, US
Get TickerSpark's AI analysis on NNVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.13M
- P/E
- -2.16
- Fwd P/E
- 2.28
- PEG
- 0.13
- P/S
- 0.00
- P/B
- 4.52
- EV/EBITDA
- -2.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -137.90%
- ROIC
- -191.48%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-525,286+0.0%
- Op Income
- $-8,306,361
- Net Income
- $-8,218,508+13.2%
- EPS
- $-0.41+34.9%
- OCF Growth
- +9.2%
- FCF Growth
- +8.8%
- 52W High
- $1.93
- 52W Low
- $0.85
- 50D MA
- $1.35
- 200D MA
- $1.31
- Beta
- 1.83
- RSI (14)
- 38
- Avg Volume
- 356.86K
No earnings-call transcripts are available for NNVC yet.
- Free Float
- 83.0%
- Shares Outstanding
- 25.55M
- Float Shares
- 21.21M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NNVC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kelly LoefflerSenate · GA | Sell | Apr 7, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 919.31K | 0 |
| Vanguard Group Inc | 605.58K | 0 |
| Geode Capital Management, LLC | 229.49K | ▲ 13.47K |
| Blackrock, Inc. | 158.75K | 0 |
| Vanguard Fiduciary Trust Co | 131.92K | 0 |
| Susquehanna International Group, Llp | 126.35K | ▲ 65.73K |
| Renaissance Technologies LLC | 98.30K | ▼ 30.30K |
| Creative Planning | 86.76K | 0 |
| Ubs Group AG | 70.40K | ▼ 28.93K |
| Northern Trust Corp | 64.17K | ▲ 12.90K |
| State Street Corp | 54.21K | 0 |
| Bridgeway Capital Management, LLC | 35.44K | ▼ 601 |
Held by 23 ETFs
Biggest fund positions in NNVC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 17 | BONIUK MILTON | other | 0 |
| Feb 21, 17 | Stephenson Fournier, PLLC | other | 0 |
| Aug 8, 22 | Diwan Anil | other | 94,471 |
| Feb 7, 20 | Jawadakar Makarand | other | 0 |
| Jun 2, 19 | Day Mark D. | other | 0 |
| May 21, 18 | BONIUK MILTON | other | 5,500,000 |
| Feb 21, 17 | BONIUK MILTON | other | 1,746,288 |
| Jul 11, 17 | BONIUK MILTON | other | 120,744 |
| May 4, 17 | BONIUK MILTON | other | 149,478 |
| Feb 21, 17 | BONIUK MILTON | other | 153,611 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNVC coverage
Recent articles, reports, and earnings notes.
No research on NNVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNVC report →NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
accessnewswire.com · Oct 20
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
accessnewswire.com · Oct 13
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
accessnewswire.com · Oct 6
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
accessnewswire.com · Oct 5
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
accessnewswire.com · Sep 29
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
accessnewswire.com · Sep 28
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
accessnewswire.com · Sep 23
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
accessnewswire.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.